The raised EPS guidance and strong Life Sciences performance are positive, but the second restructuring plan in two quarters signals ongoing margin pressure in Healthcare. Watch the Q3 earnings call for details on Xodus Medical acquisition integration and whether the restructuring savings materialize as planned.
Price Chart
Executive Summary
STERIS reported fiscal Q2 2027 results with revenue of $1.59B (+9% YoY) and adjusted EPS of $2.94, both above consensus estimates of $1.56B and $2.68. The company raised its full-year adjusted EPS guidance to $11.35-$11.55 from $11.10-$11.30, citing solid underlying performance and tariff refunds. However, the company also announced a new $45M restructuring plan (on top of a prior plan) with $25M in charges already recorded in Q2, primarily in the Healthcare segment, signaling ongoing cost pressures.
Key Financial Metrics
Key Facts
- Q2 revenue $1.59B, +9% YoY, above $1.56B consensus
- Q2 adjusted EPS $2.94, above $2.68 consensus (surprise +9.7%)
- Q2 GAAP EPS $2.19 vs $1.94 YoY
- Full-year adjusted EPS guidance raised to $11.35-$11.55 from $11.10-$11.30
- Revenue growth guidance unchanged at 7-8% as reported, 6-7% organic constant currency
- Life Sciences segment revenue +18% YoY; segment outlook raised to 9-10% growth
- New $45M restructuring plan approved in Q2, with $25M in charges recorded
- Restructuring includes facility realignment, product rationalization, primarily in Healthcare
- Annualized savings of ~$9M expected from restructuring, full benefit in fiscal 2029+
- First-half free cash flow $492.5M vs $527.7M prior year, down due to working capital
- Tariff refunds provided ~$0.18 benefit to revised EPS guidance
- Company repurchased $215.9M in shares YTD vs $111.1M prior year
Financial Impact
Q2 revenue $1.59B vs $1.56B consensus; adjusted EPS $2.94 vs $2.68 consensus; FY guidance raised by $0.25 at midpoint
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Healthcare | $1.1B | +8.6% |
| Applied Sterilization Technologies | $295.6M | +5.0% |
| Life Sciences | $170.6M | +17.7% |
Risk Factors
- Restructuring charges of $45M indicate underlying cost pressures, particularly in Healthcare
- Free cash flow declined 6.7% in H1 due to working capital drag
- AST segment growth outlook lowered to 6-7% from 7-8%
- Tariff refunds boosting EPS are non-recurring; underlying tariff costs remain at $15M/quarter
- Backlog disclosure to be discontinued in fiscal 2028, reducing visibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-070220 |
| Document: ste-20261104.htm | 0001628280-26-070220 |
| Document: 0001628280-26-070220-index-headers.html | 0001628280-26-070220 |
| Document: 0001628280-26-070220-index.html | 0001628280-26-070220 |
| Document: 0001628280-26-070220.txt | 0001628280-26-070220 |
| 8-K Data (Synthetic) | 0001628280-26-070220 |
Track record
21 reports on STE
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +17.96% at T+20 after the Oct 13, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $264.32 Now $261.91 −0.91% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $264.32 Now $261.91 −0.91% settles Nov 20
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $264.32 Now $261.91 −0.91% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $253.44 Now $261.91 +3.34% settles Nov 19
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $256.27 Now $261.91 +2.20% settles Nov 18
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $254.12 to $253.44 Now $261.91 +3.07% ▼ −0.27% −3.56% vs SPY
- Nov 4, 202612d ago 8-K Bullish 6/10 Viewing No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $254.12 to $253.44 Now $261.91 +3.07% ▼ −0.27% −3.56% vs SPY
- Oct 28, 202619d ago Press Release Neutral 2/10 Entry $232.14 to $254.12 Now $261.91 +12.82% ▲ +9.47% +14.19% vs SPY
- Oct 20, 202627d ago Press Release Neutral 1/10 Entry $221.48 to $228.49 Now $261.91 +18.25% ▲ +3.17% +3.61% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers